LNC
NEO icon

Lincoln National Corp’s NeoGenomics NEO Stock Holding History

Lincoln National Corp’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$482K – 912
2021
Q3 		$482K Sell
10,000
-265
-3% -$12.3K 0.01% 515
2021
Q2 		$464K Buy
+10,265
New +$455K 0.01% 522

Other funds holding NEO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lincoln National Corp's NEO Position: Q4 2021 in Review

Lincoln National Corp sold out of NeoGenomics (NEO) in Q4 2021, closing a stake of 10,000 shares — an estimated $482K sold.

Lincoln National Corp first reported a position in NEO in Q2 2021 and held it in 2 quarters. The position peaked at $482K in Q3 2021. 307 funds tracked by Wall St. Rank hold NEO as of Q4 2021.

  • Lincoln National Corp reported no remaining NeoGenomics position as of Q4 2021 after selling out during the quarter.
  • Lincoln National Corp sold 10,000 NeoGenomics shares in Q4 2021, an estimated $482K.
  • Lincoln National Corp first reported a position in NeoGenomics in Q2 2021 and held it in 2 quarters.
  • Lincoln National Corp's NeoGenomics position peaked at $482K in Q3 2021.
  • 307 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2021.

Based on Lincoln National Corp's 13F filing for Q4 2021, filed 26 Jan 2022.